New platform coming soon — AI-Based Analysis with Human-Generated Insights

Market News & Insights

American Analyst Ratings Updates — November 18, 2026

American Analyst Ratings Updates — November 18, 2026

Analyst Ratings (USA)

Wall Street analyst sentiment remains mixed, with selective optimism across technology, healthcare, energy and consumer staples, offset by increasing caution toward high-valuation growth stocks and industrial companies. Technology continues to attract interest, with Camtek upgraded to Outperform and Manhattan Associates receiving positive initial coverage, although Nvidia’s downgrade to Hold highlights concerns surrounding AI valuations and near-term momentum. Healthcare presents a divided outlook, with upgrades for Elevance Health and Tandem Diabetes Care offset by downgrades for Insulet and Summit Therapeutics. Energy sentiment is similarly mixed, with Exxon Mobil upgraded to Buy while Comstock Resources was downgraded. Consumer staples remain relatively defensive, with favourable initial ratings for Coca-Cola, Celsius, Keurig Dr Pepper and Monster Beverage. Financials showed strength, led by Charles Schwab’s upgrade to Strong Buy, while industrials and materials faced greater caution following downgrades for Eaton, GE Vernova and Freeport-McMoRan.

General Market Outlook: The latest analyst revisions suggest a cautiously optimistic but increasingly selective U.S. equity market. Analysts continue to favour companies with strong earnings visibility, sustainable cash flow and attractive growth prospects while becoming more cautious about elevated valuations, slowing economic growth and uncertainty surrounding interest rates. Overall, the outlook supports continued opportunities in quality growth and defensive stocks, although sector rotation and heightened volatility could limit a broad-based year-end market rally.

Updates (259)

AbbVie (ABBV) — Piper Sandler reiterated its Overweight rating with a price target of $349.00.

AbCellera Biologics (ABCL) — Lake Street Capital initiated coverage with a Buy rating and a price target of $19.00.

ACADIA Pharmaceuticals (ACAD) — Oppenheimer lowered its price target from $23.00 to $21.00, maintaining a Market Perform rating.

Adeia (ADEA) — Rosenblatt Securities reiterated its Buy rating with a price target of $35.00.

Adherex Technologies (FENC) — HC Wainwright raised its price target from $16.00 to $17.00, maintaining a Buy rating.

AECOM (ACM) — Barclays raised its price target from $73.00 to $90.00, maintaining an Equal Weight rating.

AECOM (ACM) — KeyCorp raised its price target from $78.00 to $97.00, maintaining an Overweight rating.

Affiliated Managers Group (AMG) — TD Cowen reiterated its Buy rating with a price target of $583.00.

Alnylam Pharmaceuticals (ALNY) — JPMorgan Chase & Co. reiterated its price target with a price target of $254.00.

Alnylam Pharmaceuticals (ALNY) — Rodman & Renshaw downgraded the stock to Neutral.

Amer Sports (AS) — Cantor Fitzgerald raised its price target from $46.00 to $47.00, maintaining an Overweight rating.

Amer Sports (AS) — UBS Group lowered its price target from $62.00 to $56.00, maintaining a Buy rating.

American Axle & Manufacturing (DCH) — Morgan Stanley lowered its price target from $7.00 to $6.00, maintaining an Equal Weight rating.

American Axle & Manufacturing (DCH) — TD Cowen reiterated its Buy rating with a price target of $10.00.

Antero Resources (AR) — Morgan Stanley raised its price target from $51.00 to $52.00, maintaining an Overweight rating.

APA Corporation (APA) — Morgan Stanley raised its price target from $43.00 to $44.00, maintaining an Underweight rating.

AppLovin (APP) — JPMorgan Chase & Co. reiterated its price target with a price target of $400.00.

Baidu (BIDU) — Barclays lowered its price target from $80.00 to $72.00, maintaining an Equal Weight rating.

Baidu (BIDU) — Stifel Nicolaus reiterated its price target with a price target of $83.00.

Baidu (BIDU) — Susquehanna lowered its price target from $105.00 to $75.00, maintaining a Neutral rating.

Bally’s (BALY) — Truist Financial lowered its price target from $10.00 to $9.00, maintaining a Hold rating.

BILL Holdings, Inc. (BILL) — BMO Capital Markets raised its price target from $56.00 to $68.00, maintaining a Market Perform rating.

Biogen (BIIB) — Needham & Company LLC reiterated its Buy rating.

Bitdeer Technologies Group (BTDR) — StoneX lowered its price target from $22.00 to $15.00, maintaining a Buy rating.

BlackLine (BL) — BMO Capital Markets lowered its price target from $32.00 to $30.00, maintaining a Market Perform rating.

Bridger Aerospace Group (BAER) — Canaccord Genuity Group downgraded the stock from Buy to Hold, with a price target of $1.00.

Bridger Aerospace Group (BAER) — Stifel Nicolaus downgraded the stock from Buy to Hold, with a price target of $0.25.

BrightSpring Health Services (BTSG) — BMO Capital Markets raised its price target from $80.00 to $84.00, maintaining an Outperform rating.

Brookfield (BN) — Morgan Stanley lowered its price target from $54.00 to $52.00, maintaining an Overweight rating.

Brookfield Asset Management (BAM) — Morgan Stanley raised its price target from $54.00 to $57.00, maintaining an Equal Weight rating.

Builders FirstSource (BLDR) — Royal Bank Of Canada reiterated its Sector Perform rating with a price target of $56.00.

BWX Technologies (BWXT) — TD Cowen lowered its price target from $230.00 to $180.00, maintaining a Buy rating.

Calumet (CLMT) — TD Cowen lowered its price target from $40.00 to $37.00, maintaining a Hold rating.

Camtek (CAMT) — Northland Capital upgraded the stock from Market Perform to Outperform, with a price target of $130.

Camtek (CAMT) — Northland Securities upgraded the stock from Market Perform to Outperform, with a price target of $130.00.

Cardinal Health (CAH) — Barclays raised its price target from $275.00 to $320.00, maintaining an Overweight rating.

Caterpillar (CAT) — DA Davidson reiterated its price target with a price target of $685.00.

Celsius (CELH) — Wolfe Research initiated coverage with a Outperform rating and a price target of $39.00.

Cencora (COR) — Barclays raised its price target from $350.00 to $415.00, maintaining an Overweight rating.

Ceva (CEVA) — Rosenblatt Securities reiterated its Buy rating with a price target of $49.00.

CG Oncology (CGON) — Morgan Stanley raised its price target from $102.00 to $117.00, maintaining an Overweight rating.

Charles Schwab (SCHW) — Raymond James upgraded the stock from Outperform to Strong Buy, with a price target of $135.

Charles Schwab (SCHW) — Raymond James Financial upgraded the stock from Outperform to Strong-Buy, with a price target of $135.00.

Chime Financial (CHYM) — B. Riley Financial reiterated its Buy rating with its price target from $45.00 to $55.00.

Chord Energy (CHRD) — Morgan Stanley raised its price target from $178.00 to $183.00, maintaining an Overweight rating.

Chord Energy (CHRD) — Truist Financial reiterated its price target with a price target of $197.00.

Church & Dwight (CHD) — Bank of America raised its price target from $115.00 to $125.00, maintaining a Buy rating.

Cleveland-Cliffs (CLF) — Wells Fargo & Company raised its price target from $17.00 to $18.00, maintaining an Overweight rating.

Climb Bio (CLYM) — Royal Bank Of Canada reiterated its Outperform rating with a price target of $23.00.

CNX Resources (CNX) — Morgan Stanley upgraded the stock from Underweight to Equal Weight and changed its price target from $34.00 to $36.00.

Coca-Cola (KO) — Wolfe Research initiated coverage with a Outperform rating.

Commercial Metals (CMC) — Wells Fargo & Company lowered its price target from $70.00 to $63.00, maintaining an Equal Weight rating.

Comstock Resources (CRK) — Barclays downgraded the stock to Underweight.

Comstock Resources (CRK) — Morgan Stanley downgraded the stock from Equal Weight to Underweight, with a price target of $13.00.

ConocoPhillips (COP) — Morgan Stanley raised its price target from $159.00 to $160.00, maintaining an Overweight rating.

Credicorp (BAP) — UBS Group lowered its price target from $473.00 to $458.00, maintaining a Buy rating.

Cue Biopharma (CUE) — B. Riley Financial reiterated its Buy rating.

Deere & Company (DE) — Oppenheimer reiterated its Outperform rating.

Devon Energy (DVN) — Morgan Stanley raised its price target from $64.00 to $65.00, maintaining an Overweight rating.

Diamondback Energy (FANG) — Royal Bank Of Canada reiterated its Outperform rating with a price target of $240.00.

Disc Medicine (IRON) — Morgan Stanley raised its price target from $92.00 to $104.00, maintaining an Overweight rating.

DLocal (DLO) — Truist Financial lowered its price target from $17.00 to $16.00, maintaining a Buy rating.

Docusign (DOCU) — BTIG Research raised its price target from $75.00 to $90.00, maintaining a Buy rating.

Duos Technologies Group (DUOT) — Chardan Capital lowered its price target from $9.50 to $5.50, maintaining a Neutral rating.

Dutch Bros (BROS) — Guggenheim lowered its price target from $76.00 to $62.00, maintaining a Buy rating.

Eaton (ETN) — Erste Group Bank downgraded the stock from Buy to Hold.

Ecolab (ECL) — Oppenheimer raised its price target from $320.00 to $331.00, maintaining an Outperform rating.

Ecolab (ECL) — Robert W. Baird raised its price target from $317.00 to $324.00, maintaining an Outperform rating.

Ecolab (ECL) — Stifel Nicolaus raised its price target from $337.00 to $356.00, maintaining a Buy rating.

Eikon Therapeutics (EIKN) — Morgan Stanley lowered its price target to $30.00, maintaining an Overweight rating.

Elbit Systems (ESLT) — JPMorgan Chase & Co. raised its price target from $885.00 to $900.00, maintaining a Neutral rating.

Elevance Health (ELV) — Argus upgraded the stock from Hold to Buy, with a price target of $510.00.

Energizer (ENR) — JPMorgan Chase & Co. raised its price target from $22.00 to $25.00, maintaining a Neutral rating.

Energizer (ENR) — Morgan Stanley raised its price target from $21.00 to $27.00, maintaining an Equal Weight rating.

Energizer (ENR) — UBS Group raised its price target from $22.00 to $28.00, maintaining a Neutral rating.

Enovix (ENVX) — Bank of America downgraded the stock from Neutral to Underperform and changed its price target from $5.00 to $1.00.

Entrada Therapeutics (TRDA) — Guggenheim lowered its price target from $17.00 to $13.00, maintaining a Buy rating.

EOG Resources (EOG) — Morgan Stanley raised its price target from $163.00 to $167.00, maintaining an Equal Weight rating.

EQT Corporation (EQT) — Morgan Stanley lowered its price target from $67.00 to $66.00, maintaining an Overweight rating.

Expand Energy (EXE) — Morgan Stanley lowered its price target from $123.00 to $120.00, maintaining an Overweight rating.

ExxonMobil (XOM) — Erste Group Bank upgraded the stock from Hold to Buy.

Ferguson (FERG) — Bank of America raised its price target from $315.00 to $320.00, maintaining a Buy rating.

Freeport-McMoRan (FCX) — Erste Group Bank downgraded the stock from Buy to Hold.

fuboTV (FUBO) — Barrington Research lowered its price target from $16.00 to $12.00, maintaining an Outperform rating.

fuboTV (FUBO) — BTIG Research reiterated its Neutral rating.

Futu (FUTU) — JPMorgan Chase & Co. lowered its price target from $122.00 to $103.00, maintaining a Neutral rating.

GE HealthCare Technologies (GEHC) — BTIG Research raised its price target from $83.00 to $91.00, maintaining a Buy rating.

GE Vernova (GEV) — Erste Group Bank downgraded the stock from Buy to Hold.

GeneDx (WGS) — BTIG Research reiterated its Buy rating with a price target of $85.00.

General Fusion Group (GFUZ) — Wedbush reiterated its Neutral rating with a price target of $7.00.

Generate Biomedicines (GENB) — Morgan Stanley lowered its price target from $22.00 to $21.00, maintaining an Overweight rating.

Geo Group (GEO) — JonesTrading reiterated its Buy rating with a price target of $42.75.

GH Research (GHRS) — Guggenheim raised its price target from $40.00 to $46.00, maintaining a Buy rating.

Granite Point Mortgage Trust (GPMT) — UBS Group lowered its price target to $3.00, maintaining a Neutral rating.

Gray Media (GTN) — Guggenheim raised its price target from $7.00 to $8.00, maintaining a Buy rating.

Greenwich LifeSciences (GLSI) — HC Wainwright raised its price target from $69.00 to $70.00, maintaining a Buy rating.

Guardant Health (GH) — TD Cowen reiterated its Buy rating.

HA Sustainable Infrastructure Capital (HASI) — Jefferies Financial Group reiterated its Buy rating with a price target of $46.00.

HCA Healthcare (HCA) — JPMorgan Chase & Co. raised its price target from $425.00 to $475.00, maintaining a Neutral rating.

Hershey (HSY) — TD Cowen reiterated its Hold rating with a price target of $173.00.

Home Depot (HD) — DA Davidson raised its price target from $377.00 to $390.00, maintaining a Buy rating.

Home Depot (HD) — JPMorgan Chase & Co. reiterated its price target with a price target of $390.00.

Home Depot (HD) — Mizuho lowered its price target from $390.00 to $385.00, maintaining an Outperform rating.

Home Depot (HD) — Royal Bank Of Canada lowered its price target from $342.00 to $334.00, maintaining a Sector Perform rating.

Home Depot (HD) — Sanford C. Bernstein raised its price target from $357.00 to $360.00, maintaining a Market Perform rating.

Home Depot (HD) — Truist Financial raised its price target from $373.00 to $376.00, maintaining a Buy rating.

Home Depot (HD) — UBS Group lowered its price target from $420.00 to $417.00, maintaining a Buy rating.

Hornbeck Offshore Services (HOS) — Pickering Energy Partners upgraded the stock from Neutral to Outperform.

Hyperfine (HYPR) — B. Riley Financial reiterated its Buy rating with its price target from $1.60 to $1.40.

Immix Biopharma (IMMX) — Mizuho lowered its price target from $23.00 to $22.00, maintaining an Outperform rating.

Immix Biopharma (IMMX) — Morgan Stanley raised its price target from $20.00 to $21.00, maintaining an Overweight rating.

Immunic (IMUX) — HC Wainwright reiterated its Buy rating.

Innoviva (INVA) — Piper Sandler initiated coverage with a Overweight rating and a price target of $29.00.

Insulet (PODD) — Stifel Nicolaus downgraded the stock from Buy to Hold and changed its price target from $180.00 to $165.00.

Intuitive Surgical (ISRG) — BTIG Research raised its price target from $454.00 to $513.00, maintaining a Buy rating.

Ionis Pharmaceuticals (IONS) — Guggenheim lowered its price target from $80.00 to $65.00, maintaining a Buy rating.

ITT Inc. (ITT) — TD Cowen raised its price target from $250.00 to $260.00, maintaining a Buy rating.

J. M. Smucker (SJM) — UBS Group raised its price target from $149.00 to $153.00, maintaining a Buy rating.

JD.com (JD) — Barclays lowered its price target from $38.00 to $33.00, maintaining an Overweight rating.

JD.com (JD) — Mizuho lowered its price target from $37.00 to $34.00, maintaining an Outperform rating.

JD.com (JD) — Sanford C. Bernstein lowered its price target from $40.00 to $38.00, maintaining an Outperform rating.

JD.com (JD) — StoneX reiterated its price target with a price target of $42.00.

Keurig Dr Pepper (KDP) — Wolfe Research initiated coverage with a Outperform rating and a price target of $42.00.

Klarna Group (KLAR) — Bank of America raised its price target from $19.00 to $20.00, maintaining a Buy rating.

Klarna Group (KLAR) — BMO Capital Markets lowered its price target from $14.00 to $13.00, maintaining a Market Perform rating.

Klarna Group (KLAR) — JPMorgan Chase & Co. lowered its price target from $18.00 to $17.00, maintaining a Neutral rating.

Klarna Group (KLAR) — Morgan Stanley lowered its price target from $17.00 to $14.00, maintaining an Equal Weight rating.

Lantern Pharma (LTRN) — Rodman & Renshaw downgraded the stock from Buy to Neutral.

Liberty Global (LBTYA) — Citigroup resumed coverage with a Neutral rating and a price target of $11.00.

LifeMD (LFMD) — HC Wainwright lowered its price target from $9.00 to $6.00, maintaining a Buy rating.

Liftoff Mobile (LFTO) — UBS Group raised its price target from $25.00 to $35.00, maintaining a Buy rating.

Lowe’s Companies (LOW) — TD Cowen reiterated its Hold rating with a price target of $235.00.

Lowe’s Companies (LOW) — Truist Financial reiterated its price target with a price target of $254.00.

Lumexa Imaging (LMRI) — Wells Fargo & Company raised its price target from $19.00 to $21.00, maintaining an Overweight rating.

LuxExperience B.V. (LUXE) — B. Riley Financial reiterated its Buy rating with its price target from $13.00 to $14.00.

LuxExperience B.V. (LUXE) — TD Cowen raised its price target from $12.00 to $13.50, maintaining a Buy rating.

Manhattan Associates (MANH) — JPMorgan Chase & Co. initiated coverage with a Overweight rating and a price target of $308.00.

MARA Holdings (MARA) — BTIG Research reiterated its Buy rating with a price target of $27.00.

Matador Resources (MTDR) — Morgan Stanley raised its price target from $69.00 to $70.00, maintaining an Equal Weight rating.

McDonald’s (MCD) — KeyCorp reiterated its Overweight rating.

McKesson (MCK) — Barclays raised its price target from $1,000.00 to $1,235.00, maintaining an Overweight rating.

MDU Resources Group (MDU) — TD Cowen reiterated its Hold rating with a price target of $22.00.

Micron Technology (MU) — Royal Bank Of Canada reiterated its Outperform rating with a price target of $1,500.00.

Microsoft (MSFT) — JPMorgan Chase & Co. reiterated its price target with a price target of $625.00.

Microsoft (MSFT) — Mizuho reiterated its price target with a price target of $625.00.

Microsoft (MSFT) — Oppenheimer reiterated its Outperform rating.

Microsoft (MSFT) — Piper Sandler reiterated its Overweight rating.

Microsoft (MSFT) — TD Cowen reiterated its Buy rating with a price target of $650.00.

Microsoft (MSFT) — UBS Group reiterated its Overweight rating.

Middleby (MIDD) — Oppenheimer reiterated its Outperform rating.

Midera Food Processing (MFP) — Robert W. Baird raised its price target from $40.00 to $43.00, maintaining a Neutral rating.

Millicom International Cellular (TIGO) — JPMorgan Chase & Co. upgraded the stock from Neutral to Overweight, with a price target of $105.00.

Molson Coors Beverage (TAP) — Wolfe Research initiated coverage with a Peer Perform rating.

Monster Beverage (MNST) — Wolfe Research initiated coverage with a Outperform rating.

MP Materials (MP) — Needham resumed coverage with a Buy rating and a price target of $48.

MP Materials (MP) — Needham & Company LLC initiated coverage with a Buy rating and a price target of $48.00.

Murphy Oil (MUR) — Morgan Stanley raised its price target from $37.00 to $39.00, maintaining an Underweight rating.

New York Times (NYT) — Citigroup downgraded the stock from Buy to Neutral and changed its price target from $85.00 to $76.00.

NIKE (NKE) — Barclays lowered its price target from $45.00 to $42.00, maintaining an Overweight rating.

NIKE (NKE) — BMO Capital Markets reiterated its Underperform rating.

NIKE (NKE) — BTIG Research reiterated its Buy rating.

NIKE (NKE) — JPMorgan Chase & Co. reiterated its price target with a price target of $38.00.

NIKE (NKE) — Needham & Company LLC reiterated its Hold rating.

Nucor (NUE) — Wells Fargo & Company raised its price target from $305.00 to $308.00, maintaining an Overweight rating.

NVIDIA (NVDA) — Argus reiterated its Buy rating with a price target of $220.00.

NVIDIA (NVDA) — BMO Capital Markets reiterated its Outperform rating.

NVIDIA (NVDA) — Citigroup reiterated its price target with a price target of $225.00.

NVIDIA (NVDA) — DA Davidson reiterated its Buy rating with a price target of $200.00.

NVIDIA (NVDA) — HSBC reiterated its price target with a price target of $170.00.

NVIDIA (NVDA) — Jefferies Financial Group reiterated its Buy rating with its price target from $300.00 to $250.00.

NVIDIA (NVDA) — JPMorgan Chase & Co. reiterated its Overweight rating with its price target from $215.00 to $230.00.

NVIDIA (NVDA) — KeyCorp reiterated its Sector Weight rating.

NVIDIA (NVDA) — Melius Research reiterated its price target with a price target of $185.00.

NVIDIA (NVDA) — Morgan Stanley lowered its price target from $267.00 to $260.00, maintaining an Overweight rating.

NVIDIA (NVDA) — Needham & Company LLC reiterated its Buy rating with a price target of $200.00.

NVIDIA (NVDA) — Piper Sandler reiterated its Overweight rating with its price target from $300.00 to $230.00.

NVIDIA (NVDA) — Royal Bank Of Canada reiterated its Outperform rating with a price target of $230.00.

NVIDIA (NVDA) — Summit Insights downgraded the stock from Buy to Hold.

NVIDIA (NVDA) — Susquehanna reiterated its Positive rating.

NVIDIA (NVDA) — Truist Financial reiterated its price target with a price target of $174.00.

NVIDIA (NVDA) — Wedbush raised its price target from $275.00 to $293.00, maintaining an Outperform rating.

NVIDIA (NVDA) — Wells Fargo & Company lowered its price target from $300.00 to $250.00, maintaining an Overweight rating.

Oaktree Specialty Lending (OCSL) — Keefe, Bruyette & Woods lowered its price target from $13.50 to $12.50, maintaining a Market Perform rating.

OGE Energy (OGE) — JPMorgan Chase & Co. raised its price target from $53.00 to $56.00, maintaining an Overweight rating.

Once Upon A Farm (OFRM) — JPMorgan Chase & Co. raised its price target from $13.00 to $14.00, maintaining an Overweight rating.

Oncocyte (IMDX) — Stephens reiterated its Equal Weight rating with a price target of $4.00.

OneWater Marine (ONEW) — KeyCorp reiterated its Overweight rating.

Opera (OPRA) — B. Riley Financial lowered its price target from $28.00 to $27.00, maintaining a Buy rating.

Oric Pharmaceuticals (ORIC) — Wells Fargo & Company lowered its price target from $25.00 to $23.00, maintaining an Overweight rating.

OrthoPediatrics (KIDS) — BTIG Research raised its price target from $30.00 to $40.00, maintaining a Buy rating.

Ovintiv (OVV) — Morgan Stanley raised its price target from $71.00 to $72.00, maintaining an Equal Weight rating.

Paysafe (PSFE) — Susquehanna lowered its price target from $7.00 to $3.50, maintaining a Neutral rating.

PepsiCo (PEP) — Wolfe Research initiated coverage with a Peer Perform rating.

Petroleo Brasileiro S.A. – Petrobras (PBR) — JPMorgan Chase & Co. lowered its price target from $24.00 to $23.50, maintaining an Overweight rating.

Phathom Pharmaceuticals (PHAT) — Barclays lowered its price target from $14.00 to $10.00, maintaining an Overweight rating.

Pilgrim’s Pride (PPC) — UBS Group raised its price target from $28.00 to $31.00, maintaining a Neutral rating.

Planet Fitness (PLNT) — UBS Group raised its price target from $80.00 to $83.00, maintaining a Buy rating.

Portland General Electric (POR) — JPMorgan Chase & Co. lowered its price target from $50.00 to $48.00, maintaining a Neutral rating.

Portman Ridge Finance (BCIC) — Keefe, Bruyette & Woods lowered its price target from $7.50 to $6.50, maintaining a Market Perform rating.

Prelude Therapeutics (PRLD) — HC Wainwright reiterated its Buy rating with a price target of $8.00.

Procter & Gamble (PG) — Wells Fargo & Company raised its price target from $180.00 to $188.00, maintaining an Overweight rating.

Pulmonx (LUNG) — Loop Capital reiterated its price target with a price target of $7.00.

Qualcomm (QCOM) — Robert W. Baird lowered its price target from $320.00 to $300.00, maintaining an Outperform rating.

Range Resources (RRC) — Morgan Stanley raised its price target from $45.00 to $50.00, maintaining an Equal Weight rating.

Recursion Pharmaceuticals (RXRX) — Morgan Stanley lowered its price target from $5.90 to $5.60, maintaining an Equal Weight rating.

Rein Therapeutics (RNTX) — HC Wainwright reiterated its Buy rating.

Reliance (RS) — Wells Fargo & Company raised its price target from $420.00 to $452.00, maintaining an Equal Weight rating.

Relx (RELX) — Erste Group Bank initiated coverage with a Buy rating.

Royalty Pharma (RPRX) — TD Cowen raised its price target from $68.00 to $80.00, maintaining a Buy rating.

Sabre (SABR) — Cantor Fitzgerald reiterated its Neutral rating with a price target of $2.00.

Salesforce (CRM) — BTIG Research lowered its price target from $300.00 to $250.00, maintaining a Buy rating.

Securitize (SECZ) — B. Riley Financial initiated coverage with a Buy rating and a price target of $14.00.

Securitize (SECZ) — B. Riley Securities initiated coverage with a Buy rating and a price target of $14.

ServiceTitan (TTAN) — Piper Sandler reiterated its Overweight rating with a price target of $110.00.

Sherwin-Williams (SHW) — Argus reiterated its Buy rating with a price target of $380.00.

Similarweb (SMWB) — Barclays raised its price target from $11.00 to $13.00, maintaining an Overweight rating.

Sinclair (SBGI) — Guggenheim raised its price target from $19.00 to $20.00, maintaining a Buy rating.

SKYX Platforms (SKYX) — Subscribe to MarketBeat All Access to unlock brokerage rankings lowered its price target from $2.50 to $2.00, maintaining a Buy rating.

SLR Investment (SLRC) — Keefe, Bruyette & Woods lowered its price target from $13.50 to $13.00, maintaining a Market Perform rating.

Snowflake (SNOW) — UBS Group lowered its price target from $500.00 to $450.00, maintaining a Buy rating.

SOLV Energy (MWH) — UBS upgraded the stock from Neutral to Buy, with a price target of $37.

SOLV Energy (MWH) — UBS Group upgraded the stock from Neutral to Buy and changed its price target from $50.00 to $37.00.

Spire (SR) — Mizuho raised its price target from $93.00 to $96.00, maintaining an Outperform rating.

Steel Dynamics (STLD) — Wells Fargo & Company raised its price target from $271.00 to $285.00, maintaining an Overweight rating.

Stryker (SYK) — BTIG Research raised its price target from $304.00 to $345.00, maintaining a Buy rating.

Summit Therapeutics (SMMT) — Bernstein downgraded the stock from Market Perform to Underperform, with a price target of $8.30.

Summit Therapeutics (SMMT) — Sanford C. Bernstein downgraded the stock from Market Perform to Underperform and changed its price target from $11.90 to $8.30.

Tandem Diabetes Care (TNDM) — Lake Street Capital initiated coverage with a Buy rating.

Tandem Diabetes Care (TNDM) — Piper Sandler initiated coverage with a Neutral ? Overweight rating.

Tandem Diabetes Care (TNDM) — Raymond James Financial upgraded the stock from Market Perform to Strong-Buy.

Tandem Diabetes Care (TNDM) — Stifel Nicolaus upgraded the stock from Hold to Buy and changed its price target from $22.00 to $26.00.

Tandem Diabetes Care (TNDM) — UBS Group upgraded the stock from Neutral to Buy.

Tencent Music Entertainment Group (TME) — Mizuho lowered its price target from $15.00 to $14.00, maintaining an Outperform rating.

Tyler Technologies (TYL) — TD Cowen raised its price target from $450.00 to $475.00, maintaining a Buy rating.

Tyler Technologies (TYL) — Truist Financial reiterated its Buy rating with its price target from $440.00 to $500.00.

Tyson Foods (TSN) — Bank of America raised its price target from $56.00 to $65.00, maintaining a Neutral rating.

uniQure (QURE) — HC Wainwright lowered its price target from $80.00 to $65.00, maintaining a Buy rating.

United States Antimony (UAMY) — B. Riley Financial lowered its price target from $10.00 to $6.00, maintaining a Buy rating.

Vericel (VCEL) — BTIG Research reiterated its Neutral rating.

Veritone (VERI) — HC Wainwright initiated coverage with a Buy rating and a price target of $2.00.

Viking (VIK) — Barclays raised its price target from $102.00 to $111.00, maintaining an Overweight rating.

Viking (VIK) — JPMorgan Chase & Co. lowered its price target from $131.00 to $122.00, maintaining an Overweight rating.

Viking (VIK) — Morgan Stanley raised its price target from $92.00 to $100.00, maintaining an Equal Weight rating.

Viking (VIK) — Wells Fargo & Company raised its price target from $118.00 to $120.00, maintaining an Overweight rating.

Vista Energy (VIST) — UBS Group raised its price target from $80.00 to $100.00, maintaining a Buy rating.

VolitionRx (VNRX) — Freedom Broker downgraded the stock from Buy to Hold.

Walt Disney (DIS) — Bank of America raised its price target from $125.00 to $135.00, maintaining a Buy rating.

Walt Disney (DIS) — Barclays raised its price target from $115.00 to $135.00, maintaining an Overweight rating.

Walt Disney (DIS) — Guggenheim raised its price target from $120.00 to $135.00, maintaining a Buy rating.

Walt Disney (DIS) — JPMorgan Chase & Co. raised its price target from $137.00 to $140.00, maintaining an Overweight rating.

Walt Disney (DIS) — Needham & Company LLC raised its price target from $125.00 to $135.00, maintaining a Buy rating.

Walt Disney (DIS) — Raymond James Financial reiterated its Outperform rating with a price target of $133.00.

Walt Disney (DIS) — Rosenblatt Securities raised its price target from $126.00 to $141.00, maintaining a Buy rating.

Walt Disney (DIS) — Wells Fargo & Company raised its price target from $132.00 to $140.00, maintaining an Overweight rating.

XPENG (XPEV) — Barclays lowered its price target from $14.00 to $12.00, maintaining an Underweight rating.

York Space Systems (YSS) — Barclays lowered its price target from $11.00 to $5.00, maintaining an Equal Weight rating.

Zoom Communications (ZM) — BTIG Research lowered its price target from $125.00 to $115.00, maintaining a Buy rating.

Zoom Communications (ZM) — Rosenblatt Securities reiterated its Buy rating with a price target of $130.00.

ZoomInfo Technologies (GTM) — Morgan Stanley lowered its price target from $5.00 to $4.00, maintaining an Equal Weight rating.

Join the discussion

Your email address will not be published. Required fields are marked *